| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | Epothilone B | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |